Details

Autor(en) / Beteiligte

• Westendorf, Kathryn
• Žentelis, Stefanie
• Wang, Lingshu
• Foster, Denisa
• Vaillancourt, Peter
• Wiggin, Matthew
• Lovett, Erica
• van der Lee, Robin
• Hendle, Jörg
• Pustilnik, Anna
• Sauder, J. Michael
• Kraft, Lucas
• Hwang, Yuri
• Siegel, Robert W.
• Chen, Jinbiao
• Heinz, Beverly A.
• Higgs, Richard E.
• Kallewaard, Nicole L.
• Jepson, Kevin
• Goya, Rodrigo
• Smith, Maia A.
• Collins, David W.
• Pellacani, Davide
• Xiang, Ping
• de Puyraimond, Valentine
• Ricicova, Marketa
• Devorkin, Lindsay
• Pritchard, Caitlin
• O’Neill, Aoise
• Dalal, Kush
• Panwar, Pankaj
• Dhupar, Harveer
• Garces, Fabian A.
• Cohen, Courtney A.
• Dye, John M.
• Huie, Kathleen E.
• Badger, Catherine V.
• Kobasa, Darwyn
• Audet, Jonathan
• Freitas, Joshua J.
• Hassanali, Saleema
• Hughes, Ina
• Munoz, Luis
• Palma, Holly C.
• Ramamurthy, Bharathi
• Cross, Robert W.
• Geisbert, Thomas W.
• Menachery, Vineet
• Lokugamage, Kumari
• Borisevich, Viktoriya
• Lanz, Iliana
• Anderson, Lisa
• Sipahimalani, Payal
• Corbett, Kizzmekia S.
• Yang, Eun Sung
• Zhang, Yi
• Shi, Wei
• Zhou, Tongqing
• Choe, Misook
• Misasi, John
• Kwong, Peter D.
• Sullivan, Nancy J.
• Graham, Barney S.
• Fernandez, Tara L.
• Hansen, Carl L.
• Falconer, Ester
• Mascola, John R.
• Jones, Bryan E.
• Barnhart, Bryan C.

Titel

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Ist Teil von

• Cell reports (Cambridge), 2022-05, Vol.39 (7), p.110812-110812, Article 110812

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants. [Display omitted] •LY-CoV1404 potently neutralizes SARS-CoV-2 Omicron, BA.2 Omicron, and Delta variants•No loss of potency against currently circulating variants•Binding epitope on RBD of SARS-CoV-2 is rarely mutated based on current GISAID data•Breadth of neutralizing activity and potency supports clinical development Westendorf et al. show that LY-CoV1404 is a potent SARS-CoV-2-binding antibody that neutralizes all known variants of concern and that its epitope is rarely mutated.